NCT05603715

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: University of Vermont Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.

Detailed description

This is a 13-15 week open-label, dose escalation trial of pyridostigmine 60-180mg three times a day (TID) for the treatment of constipation in patients with Parkinson disease.

Conditions

• Parkinson Disease
• Constipation

Interventions

Type	Name	Description
DRUG	Pyridostigmine Bromide	Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks

Timeline

• Start date: 2022-08-10
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2022-11-03
• Last updated: 2026-02-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study